Treatment for Positive Preoperative MRSA Screening
Treat all MRSA-positive patients scheduled for surgery with intranasal mupirocin 2% twice daily for 5 days, with or without chlorhexidine gluconate soap (40 mg/mL), completing the regimen 1-2 weeks before surgery 1.
Decolonization Protocol
The evidence strongly supports decolonization for MRSA carriers before surgery:
- Mupirocin nasal ointment 2%: Apply twice daily for 5 days
- Chlorhexidine gluconate soap (40 mg/mL): Daily bathing during the same 5-day period (optional but recommended)
- Timing: Complete the regimen as close to surgery as possible, ideally 1-2 weeks preoperatively 1
The 2024 European guidelines provide a strong recommendation with moderate certainty for this approach in cardiac and orthopedic surgery, with conditional recommendation for other surgical procedures 1. This is reinforced by cardiac surgery data showing risk-adjusted reductions in MRSA colonization (OR 0.53), transmission (IRR 0.29), and surgical site infections (OR 0.58) with this protocol 2.
Antibiotic Prophylaxis Considerations
For MRSA carriers, standard cefazolin prophylaxis is insufficient:
- Add vancomycin or teicoplanin to the prophylactic regimen for MRSA-positive patients
- Evidence from orthopedic trauma shows 22.73% developed MRSA SSI with cefuroxime alone versus 0% with glycopeptide prophylaxis 3
- Number needed to treat is 5 to prevent one MRSA SSI by using appropriate glycopeptide coverage 3
Critical Implementation Points
Verify decolonization completion: If the 5-day mupirocin course cannot be completed preoperatively, patients should complete it postoperatively 1. For elective surgery, consider postponing the procedure to allow completion if feasible and safe.
Rescreen if indicated: In high-risk procedures (joint arthroplasty, cardiac surgery), consider rescreening approximately 2 weeks before surgery to confirm eradication 4. Studies show 3.6% failure rates in eradication, and these patients remain at risk 4.
Contact isolation: MRSA-positive patients should receive contact isolation precautions perioperatively 2.
Common Pitfalls to Avoid
The most critical error is failure to treat identified carriers—one study found that among patients who developed MRSA SSI despite positive screening, only 1 of 5 received decolonization treatment 5. This represents a complete breakdown in the screening-to-treatment pathway.
Do not rely on nasal screening alone: While most MRSA colonization is nasal (55% in one series), 5% of carriers had negative nasal cultures but positive cultures from groin or perianal sites 6. However, for practical purposes, nasal screening with targeted decolonization remains the standard approach.
Strength of Evidence
The guideline recommendation is based on 9 RCTs performed between 2002-2020, though notably these primarily enrolled MSSA carriers with the assumption that decolonization efficacy translates to MRSA 1. Real-world orthopedic data supports this assumption, showing only 0.35% deep infection rate in screened and treated populations 4.
The strongest evidence exists for cardiac and orthopedic surgery, where prosthetic material and immunocompromised states amplify the consequences of MRSA SSI 1. The intervention is cost-effective and has minimal adverse effects, making it appropriate even with conditional evidence in other surgical contexts.